The objective of this study was to analyze this issue in a German family practice setting by examining FP prescription practices for patients with Diabetes mellitus type 2 (DM2) using the case of the incretin mimetics Dipeptidyl peptidase-4 (DDP-4) inhibitors and Glucagon-like peptide-1 (GLP-1) agonists. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.